DGM
IMVT icon

Darwin Global Management’s Immunovant IMVT Stock Holding History

Darwin Global Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,818,371
Closed -$69.8M – 10
2023
Q3 		$69.8M Buy
+1,818,371
New +$41.1M 24.57% 2
2021
Q2 		– Sell
-65,849
Closed -$1.06M – 16
2021
Q1 		$1.06M Sell
65,849
-133,420
-67% -$3.52M 0.21% 10
2020
Q4 		$9.2M Buy
+199,269
New +$9.21M 2.57% 6

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Darwin Global Management's IMVT Position: Q4 2023 in Review

Darwin Global Management sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 1,818,371 shares — an estimated $69.8M sold.

Darwin Global Management first reported a position in IMVT in Q4 2020 and held it in 3 quarters. The position peaked at $69.8M in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

  • Darwin Global Management reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
  • Darwin Global Management sold 1,818,371 Immunovant shares in Q4 2023, an estimated $69.8M.
  • Darwin Global Management first reported a position in Immunovant in Q4 2020 and held it in 3 quarters.
  • Darwin Global Management's Immunovant position peaked at $69.8M in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Darwin Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.